ADMA Biologics, Inc.

NasdaqGM:ADMA Stok Raporu

Piyasa değeri: US$4.5b

ADMA Biologics Yönetim

Yönetim kriter kontrolleri 3/4

ADMA Biologics' CEO is Adam Grossman, appointed in Jan 2007, has a tenure of 17.83 years. total yearly compensation is $6.04M, comprised of 12.4% salary and 87.6% bonuses, including company stock and options. directly owns 1.08% of the company’s shares, worth $48.85M. The average tenure of the management team and the board of directors is 0.8 years and 12.3 years respectively.

Anahtar bilgiler

Adam Grossman

İcra Kurulu Başkanı

US$6.0m

Toplam tazminat

CEO maaş yüzdesi12.4%
CEO görev süresi17.8yrs
CEO sahipliği1.1%
Yönetim ortalama görev süresiless than a year
Yönetim Kurulu ortalama görev süresi12.3yrs

Son yönetim güncellemeleri

Recent updates

ADMA Biologics, Inc.'s (NASDAQ:ADMA) 27% Price Boost Is Out Of Tune With Revenues

Oct 09
ADMA Biologics, Inc.'s (NASDAQ:ADMA) 27% Price Boost Is Out Of Tune With Revenues

ADMA Biologics: Riding High On ASCENIV's Success

Oct 02

ADMA Biologics, Inc.'s (NASDAQ:ADMA) Intrinsic Value Is Potentially 57% Above Its Share Price

Sep 06
ADMA Biologics, Inc.'s (NASDAQ:ADMA) Intrinsic Value Is Potentially 57% Above Its Share Price

ADMA Biologics' (NASDAQ:ADMA) Strong Earnings Are Of Good Quality

Aug 16
ADMA Biologics' (NASDAQ:ADMA) Strong Earnings Are Of Good Quality

ADMA Biologics: A Compelling GARP Stock For Biotech Investors

Jul 27

ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Jul 24
ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?

Jul 17
Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?

Is ADMA Biologics, Inc. (NASDAQ:ADMA) Trading At A 43% Discount?

May 30
Is ADMA Biologics, Inc. (NASDAQ:ADMA) Trading At A 43% Discount?

ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next

May 13
ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next

Giving ADMA Biologics A Well-Deserved 'Booyah'

May 12

ADMA Biologics, Inc.'s (NASDAQ:ADMA) Prospects Need A Boost To Lift Shares

May 08
ADMA Biologics, Inc.'s (NASDAQ:ADMA) Prospects Need A Boost To Lift Shares

Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?

Apr 04
Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?

Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)

Apr 03

ADMA Biologics: On A Roll Entering 2024

Jan 19

Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?

Jan 09
Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?

ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement

Jan 09
ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement

We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

Oct 25
We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

Jun 10
We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet

May 12
The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet

ADMA Biologics: Strong Growth Is Clearing The Path To Profitability

Aug 21

ADMA Biologics GAAP EPS of -$0.07, revenue of $33.9M

Aug 10

ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt

Jun 01
ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt

ADMA Biologics: A Path To Profits Looks Clear

May 12

ADMA: Pertinent Updates

Apr 18

ADMA Biologics' 2021 Numbers Showed Continued Strong Execution

Mar 29

ADMA Biologics: 2021 Was Tough

Jan 18

CEO Tazminat Analizi

Adam Grossman'un ücretlendirmesi ADMA Biologics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

US$35m

Mar 31 2024n/an/a

-US$4m

Dec 31 2023US$6mUS$750k

-US$28m

Sep 30 2023n/an/a

-US$23m

Jun 30 2023n/an/a

-US$40m

Mar 31 2023n/an/a

-US$48m

Dec 31 2022US$3mUS$637k

-US$66m

Sep 30 2022n/an/a

-US$70m

Jun 30 2022n/an/a

-US$73m

Mar 31 2022n/an/a

-US$78m

Dec 31 2021US$4mUS$618k

-US$72m

Sep 30 2021n/an/a

-US$74m

Jun 30 2021n/an/a

-US$74m

Mar 31 2021n/an/a

-US$75m

Dec 31 2020US$2mUS$600k

-US$76m

Sep 30 2020n/an/a

-US$67m

Jun 30 2020n/an/a

-US$61m

Mar 31 2020n/an/a

-US$54m

Dec 31 2019US$2mUS$536k

-US$48m

Sep 30 2019n/an/a

-US$56m

Jun 30 2019n/an/a

-US$59m

Mar 31 2019n/an/a

-US$61m

Dec 31 2018US$2mUS$536k

-US$66m

Sep 30 2018n/an/a

-US$61m

Jun 30 2018n/an/a

-US$61m

Mar 31 2018n/an/a

-US$55m

Dec 31 2017US$3mUS$494k

-US$44m

Tazminat ve Piyasa: Adam's total compensation ($USD6.04M) is about average for companies of similar size in the US market ($USD6.66M).

Tazminat ve Kazançlar: Adam's compensation has been consistent with company performance over the past year.

CEO

Adam Grossman (47 yo)

17.8yrs

Görev süresi

US$6,039,649

Tazminat

Mr. Adam S. Grossman serves as Director at BioFlorida Inc since August 2021. He is the Co-Founder of ADMA Biologics, Inc. and has been its Chief Executive Officer and President since October 2011 and 2007...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Adam Grossman
Co-Founder17.8yrsUS$6.04m1.08%
$ 48.8m
Jerrold Grossman
Co-Founder & Vice Chairman of the Board17.8yrsUS$284.72k0.22%
$ 9.9m
Brad Tade
CFO & Treasurerless than a yearVeri yok0.092%
$ 4.2m
Kaitlin Kestenberg
COO & Senior VP of Complianceless than a yearVeri yok0.055%
$ 2.5m
Drew Pantello
Vice President of Marketing & Corporate Developmentno dataVeri yokVeri yok
John Hafl
Executive Director of Salesless than a yearVeri yokVeri yok
Cindy Petersen
Vice President of Human Resources2.8yrsVeri yokVeri yok
Skyler Bloom
Senior Director of Business Development & Corporate Strategyno dataVeri yokVeri yok

0.8yrs

Ortalama Görev Süresi

49yo

Ortalama Yaş

Deneyimli Yönetim: ADMA's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Adam Grossman
Co-Founder17.8yrsUS$6.04m1.08%
$ 48.8m
Jerrold Grossman
Co-Founder & Vice Chairman of the Board17.8yrsUS$284.72k0.22%
$ 9.9m
Bryant Fong
Independent Director12.5yrsUS$280.72k0.026%
$ 1.2m
Steven Elms
Independent Chairman17.8yrsUS$290.22k0.022%
$ 1.0m
Young Kwon
Independent Director3.1yrsUS$272.34k0.098%
$ 4.4m
Michael Green
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Lawrence Guiheen
Independent Director12.3yrsUS$275.09k0.061%
$ 2.8m
Roy Chemaly
Member of Scientific Advisory Board10.4yrsVeri yokVeri yok
Jordan Orange
Member of Scientific Advisory Board10.4yrsVeri yokVeri yok
Alison Finger
Independent Director1.1yrsUS$231.12kVeri yok
Jean-Laurent Casanova
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Ann Falsey
Member of Scientific Advisory Boardno dataVeri yokVeri yok

12.3yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ADMA's board of directors are seasoned and experienced ( 12.3 years average tenure).